Whether it is a drug-resistant strain of bacteria, or cancer cells that no longer react to the drugs intended to kill them, diverse mutations make cells resistant to chemicals, and "second generation" approaches are needed.
Now, a team of Penn State engineers may have a way to predict which mutations will occur in people, creating an easier path to create effective pharmaceuticals.
"Structure-based drug design works very well," said Justin Pritchard, assistant professor of biomedical engineering and holder of the Dorothy Foehr Huck and J. Lloyd Huck Early Career Entrepreneurial Professorship.
"It is an amazing ecosystem of technology, but you still have to point it at a set of resistance mutations."
Standard practice to develop drugs is to model the structure of chemicals and their cellular targets to kill specific pathogens or cancer cells.
Once mutations begin to change the cells, treatment requires new drugs.
However, a variety of mutations may occur and drug developers need to target the appropriate mutation to kill the pathogen or the cancer cells.
The researchers wanted to discover what drives which mutations to grow out in the real world so that they could choose the most effective mutations to target.
They report in Cell Reports that they found that the most drug-resistant mutation was not necessarily the mutation that dominated.
"Survival of the fittest" did not always hold and targeting should aim at the most probable mutation rather than the most resistant, at least for some cancers.
"We need to not just understand the biophysics," said Pritchard. "We also need to understand the evolutionary dynamics."
Drug resistance is a problem when treating diseases caused by bacteria, viruses and cancers, but the researchers chose to investigate mutations in cancers because understanding mutations in cancer cells is simpler.
Mutations in bacteria and virus have two components -- what happens within the cells and what happens when the bacteria or viruses spread from host to host.
Because cancer is not, in humans, contagious, working with cancer cells removes a portion of the potential source of mutations.
"If we take out the community aspect of transmission, we can study just the de novo, or 'from nothing,' generation of mutations," said Pritchard.
The researchers looked at existing data for leukaemia and three other types of cancer.
The leukaemia database was the largest and most complete.
They used algorithms similar to those used in modelling how chemical reactions in chemical physics take place.
In this case, they used the simulations to model how evolution works.
"We are trying to create a generalised approach to getting the numbers that we use in the models," said Pritchard.
"To do this we did not 'fit' the model, but used data obtained from experiments and scaling."
Creating a way to obtain data for generalised cases rather than individuals would increase the possibility of using this method for a variety of pathogens.
"We ran the model and it matched clinical data to a degree much better than I ever expected," said Pritchard.
"We did this from first principles (basic assumptions)."
As cancer cells divide, errors that are made in the copying of DNA result in mutations.
One letter of DNA might be mistakenly replaced with another, but these mistakes are not completely random.
Some letters are more easily substituted for others, and so these mutations happen more often.
This creates a mutation bias -- some substitutions are more likely.
Thus the likeliness of a mistake, and not the reduction in sensitivity to drugs, can predict the resistance mutations that real patients develop.
"We shouldn't always focus on the strongest resistance mutation because there are other evolutionary forces that dictate what happens in the real world," said Pritchard.
"Sometimes drug resistance relies on biased random events."
The researchers found that biased random mutations played a big part in the evolution of resistance in leukaemia.
They found similar results with breast, prostate and stomach cancers, although the effect size was not as large.
"The data are not quite as strong in the prostate and breast cancer setting," said Pritchard.
"In non-small cell lung cancer we didn't see this effect at all."
According to the researchers, there are lots of places where evolutionary bias creates an abundance of mutations that are not the most resistant strains, but it is a spectrum with leukaemias on one end; breast, prostate and stomach cancers in the middle; and non-small cell lung cancer on the other end.
"Our analysis establishes a principle for rational drug design: When evolution favours the most probable mutant, so should drug design," the researchers said.
Source: Pennsylvania State University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.